Showing results (91-100 of 191) with videos related to

Sort By:
Pageof 20
Oncotargets and Therapy|September 8, 2016
Noninvasive monitoring of the genetic evolution of EGFR-mutant non-small-cell lung cancer by analyzing circulating tumor DNA during combination chemotherapy with gefitinib and pemetrexed or S-1Yoshiro Nakahara, Yusuke Takagi, Yukio Hosomi, et al.
Respiratory Investigation|January 1, 2022
Correlation between body mass index and efficacy of anti-PD-1 inhibitor in patients with non-small cell lung cancerAkiko Tateishi, Hidehito Horinouchi, Tatsuya Yoshida, et al.
Respiratory Investigation|September 11, 2022
Liquid biopsy for the detection of resistance mutations to ROS1 and RET inhibitors in non-small lung cancers: A case series studyYoshitaka Seki, Tatsuya Yoshida, Takashi Kohno, et al.
Lung Cancer (Amsterdam, Netherlands)|February 28, 2025
Evolving treatments and prognosis in Stage IV non-small cell lung cancer: 20 years of progress of novel therapiesHironori Satoh, Yusuke Okuma, Yuki Shinno, et al.
JTO Clinical and Research Reports|February 16, 2024
Distinct Progression and Efficacy of First-Line Osimertinib Treatment According to Mutation Subtypes in Metastatic NSCLC Harboring EGFR MutationsYuki Takeyasu, Tatsuya Yoshida, Ken Masuda, et al.
Cancer Science|January 19, 2021
IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patientsMakoto Nishio, Haruhiro Saito, Koichi Goto, et al.
Anticancer Research|January 30, 2026
Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance StatusYoh Yamaguchi, Tatsuya Yoshida, Ryoko Inaba Higashiyama, et al.
Frontiers in Oncology|February 11, 2022
CD70 in Thymic Squamous Cell Carcinoma: Potential Diagnostic Markers and Immunotherapeutic TargetsJumpei Kashima, Tsunekazu Hishima, Yusuke Okuma, et al.
Future Oncology (London, England)|January 17, 2022
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC: a study protocol of phase 2 study (UNICORN/TCOG1901)Yusuke Okuma, Mototsugu Shimokawa, Kana Hashimoto, et al.
Clinical Lung Cancer|May 26, 2022
Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic TumorYuki Shinno, Akihiko Yoshida, Ken Masuda, et al.
Pageof 20